Physician profile
Aaron Mark Mcguire
NPI 1245548171
$1,279.06
in general payments reported to CMS, 2019-2025
13 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $58.54 · 2021: $71.06 · 2022: $109 · 2023: $267 · 2024: $258 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $914.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $482.24 | 2022-2025 | |
| Rxsight INC | $214.35 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Tarsus Pharmaceuticals, INC. | $124.21 | 2024 | |
| Novartis Pharmaceuticals Corporation | $119.73 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $113.33 | 2019-2020 | |
| Alcon Vision LLC | $53.41 | 2020-2024 | Rocklatan |
| Allergan, INC. | $42.26 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $38.51 | 2024 | Syfovre |
| Dompe US, INC. | $37.21 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $15.16 | 2019 | |
| Genentech USA, INC. | $13.89 | 2024 | Vabysmo |
| Oyster Point Pharma, INC. | $13.04 | 2023 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Mcguire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.